Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. Read full Trend Edge analysis →
| Current Price | $3.51 |
|---|---|
| Market Cap | $7.6M |
| Float | 4.3M |
| Shares Outstanding | 2.1M |
| P/E (Forward) | 6.32 |
| Price/Sales (TTM) | 18.73 |
| vs. Analyst Target | +1324.5% to analyst PT |
| Operating Margin (TTM) | -2488.67% |
| Revenue (TTM) | $405,000 |
| Dividend Rate | None |
| Analyst Target Price | $50.00 (2 analysts) |
| Year | Revenue | Net Income | Gross Profit | EBITDA |
|---|---|---|---|---|
| 2020 | $763,000 | -$14.4M | $763,000 | -$14.1M |
| 2021 | $853,000 | -$12.6M | $853,000 | -$12.8M |
| 2022 | $810,000 | -$10.2M | $810,000 | -$10.1M |
| 2023 | $743,000 | -$7.6M | $743,000 | -$8.2M |
| 2024 | $674,000 | -$7.9M | $674,000 | -$8.1M |
| 2025 | $408,212 | -$9.9M | $384,022 | -$10.0M |
| Quarter | Revenue | Net Income |
|---|---|---|
| Sep 2024 | $179,000 | -$2.0M |
| Dec 2024 | $179,000 | -$2.0M |
| Mar 2025 | $101,000 | -$2.4M |
| Jun 2025 | $101,000 | -$2.4M |
| Institutional Ownership | 1.5% |
|---|---|
| Short Float | 0.4% |
| % of All Funds Holding | 0.17% |
| Number of Funds Holding | 13 |
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
| Timeframe | SMA | Value | Trend Context |
|---|---|---|---|
| Weekly | 10-Week SMA | $3.28 | Near-term / short-term trend |
| Weekly | 40-Week SMA | $6.91 | Medium-term trend |
| Weekly | 80-Week SMA | $17.75 | Cyclical trend (business cycle) |
| Weekly | 200-Week SMA | $51.99 | Secular trend (multi-year) |
| Monthly | 10-Month SMA | $6.30 | Near-term monthly trend |
| Monthly | 20-Month SMA | $17.74 | Medium-term monthly trend |
| Monthly | 40-Month SMA | $33.11 | Secular monthly trend |
Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
| Price Level | Type | Volume Ratio | Age |
|---|---|---|---|
| $4.50 | resistance | 5.49x | 1 months ago |
| $7.00 | resistance | 3.34x | 4 months ago |
| $8.20 | resistance | 9.02x | 5 months ago |
| $12.20 | resistance | 1.41x | 6 months ago |
| $20.80 | resistance | 1.07x | 9 months ago |
| Timeframe | Avg Return | Median | Win Rate | Best | Worst |
|---|---|---|---|---|---|
| Gap | -1.69% | -0.43% | 34.78% | 10.24% | -47.83% |
| 1 Day | -0.82% | -0.62% | 41.30% | 18.64% | -60.29% |
| 1 Week | -1.39% | -0.76% | 41.30% | 21.57% | -59.03% |
| 2 Weeks | -2.17% | -1.63% | 34.78% | 35.82% | -60.83% |
| 1 Month | -0.94% | -5.48% | 32.61% | 144.05% | -50.72% |
Next earnings: April 13, 2026
| Month | Avg Return | Win Rate | Samples |
|---|---|---|---|
| Jan | -6.6% | 28.6% | 14 |
| Feb | 0.1% | 57.1% | 14 |
| Mar | -7.9% | 42.9% | 14 |
| Apr | -6.2% | 28.6% | 14 |
| May | -2.9% | 38.5% | 13 |
| Jun | -1.4% | 30.8% | 13 |
| Jul | -2.3% | 30.8% | 13 |
| Aug | -3.2% | 30.8% | 13 |
| Sep | 4.7% | 38.5% | 13 |
| Oct | -5.4% | 30.8% | 13 |
| Nov | 6.6% | 61.5% | 13 |
| Dec | -10.1% | 21.4% | 14 |
| Day | Avg Return | Win Rate | Samples |
|---|---|---|---|
| Monday | -0.24% | 38.8% | 637 |
| Tuesday | -0.28% | 38.6% | 697 |
| Wednesday | -0.04% | 38.6% | 695 |
| Thursday | -0.15% | 37.2% | 681 |
| Friday | 0.20% | 42.0% | 681 |
Institutional holder breakdown coming soon.
Total institutional ownership: 1.5%
Founder-led management: Pnina Fishman (Founder, Chief Scientific Officer & Executive Chairperson)
Full insider transaction history and smart buy/sell sentiment summary available on Trend Edge.
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Can Fite Biopharma Ltd ADR (CANF) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.
Get the full AI Consult analysis for CANF on Trend Edge →